Regeneron Pharmaceuticals (REGN) has disclosed a new risk, in the Capital Markets category.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Regeneron Pharmaceuticals faces significant risks due to tariffs and trade restrictions, which could materially impact its operations and financial health. The imposition of tariffs by the United States and other countries, including potential new tariffs on pharmaceutical imports, poses a threat to the company’s supply chain and cost structure. Although pharmaceutical products are currently exempt from certain tariffs, the raw materials necessary for production are not, leading to increased operational costs. Additionally, ongoing investigations and trade agreements could further complicate the situation, potentially resulting in higher tariffs and retaliatory measures that may adversely affect Regeneron’s financial condition.
Overall, Wall Street has a Strong Buy consensus rating on REGN stock based on 17 Buys, 1 Sell and 3 Holds.
To learn more about Regeneron Pharmaceuticals’ risk factors, click here.